125 0 Kommentare Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024. - Seite 2

The reason for the delay in publishing the 2023 annual report relate to i) the ongoing discussions with legal counsel and our moratorium administrator regarding the treatment of assets subject to enforcement actions undertaken by Spexis' major creditor (SPRIM Global Investments, as announced on November 29, 2023, and which we allege are wrongful) and ii) ongoing, good faith negotiations with SPRIM towards a mutually acceptable resolution of said dispute. Accordingly, the audit costs have not been approved at this stage and a further extension may be required in respect to audited accounts. The company firmly expects to publish unaudited financial statements by the end of May 2024.

About Spexis

Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com.

For further information please contact:

*For Investors:* Martin Jakobovic Head of Finance & acting Chief Financial Officer Spexis AG +41 61 567 16 00 IR@spexisbio.com	*For Media:* Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 9256 feldhaus@feldhaus-partner.ch

Disclaimer

Lesen Sie auch

Pandemiegefahr

Vogelgrippe-Welle voraus? 9 Aktien, die profitieren könnten

04.06.24, 18:28

1 Kommentar

Prognose angehoben

Diese Aktie ist heute der Top-Gewinner im Nasdaq!

03.06.24, 19:04

Rechtzeitig positionieren

Indexanpassungen: TUI und Rational vor Aufstieg, Morphosys und SMA fallen heraus

03.06.24, 15:34

"Potenziell bedeutend"

BioNTech: Neue Daten für Lungenkrebs-Therapie – zündet die Aktie heute?

03.06.24, 10:54

This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Seite 2 von 3

◄ Seite 1 Seite 3 ►